Next Generation Antibody Therapy for Reversal of Amyloidosis
About Immutrin
Immutrin is a biotechnology company developing next generation antibody therapy to deplete systemic amyloid deposits and reverse amyloidosis.
The Company’s lead asset is being developed for the treatment of ATTR cardiomyopathy, a serious and progressive form of amyloidosis. Immutrin's antibody is a potential best-in-class therapy, with a unique mechanism of action designed to selectively and exclusively remove established amyloid fibrils.
Immutrin was co-founded by Cambridge Innovation Capital, academic founders Professor Sir Mark Pepys FRS, Nobel Laureate Sir Gregory Winter FRS and Professor Daniel Christ and is built on decades of scientific and clinical leadership in amyloidosis combined with groundbreaking antibody expertise in drug development. Our antibody discovery was enabled by Professor Vittorio Bellotti’s seminal discoveries of the pathophysiological mechanisms of amyloid formation. Immutrin is led by an experienced management team and supported by other leading global investors including Frazier Life Sciences, F-Prime, Qiming Venture Partners and SR One.
Founders and Advisors
Prof Sir Mark Pepys FRS
- Emeritus Professor of Medicine at UCL
- Honorary Fellow, Trinity College, Cambridge
- Founder of NHS National Amyloidosis Centre
Sir Gregory Winter FRS
- 2018 Chemistry Nobel Laureate
- Pioneer of therapeutic monoclonal antibodies
- Co-founder of CAT, Domantis and Bicycle Therapeutics
Prof Daniel Christ
- Professor Faculty of Medicine, UNSW, Sydney
- Pioneer of monoclonal antibody technology, phage display, single domains
- Founding Director, Centre for Targeted Therapy, GIMR
Prof Vittorio Bellotti
- Scientific Director, Fondazione IRCCS Policlinico San Matteo, Pavia
- Professor Department of Molecular Medicine, University of Pavia
- Emeritus Professor of Medical Biochemistry at UCL
Investors
Latest News
Immutrin emerges from stealth with $87M Series A investment from top-tier investors.
If you would like to find out more about Immutrin, please get in touch.